Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Heartseed, Inc. ( (JP:219A) ).
Heartseed Inc. has announced the submission of a clinical trial notification to Japan’s Pharmaceuticals and Medical Devices Agency for its HS-005 therapy, marking a significant step towards treating severe heart failure. The trial aims to assess the safety and efficacy of the therapy in 14 patients, with plans to begin treatment in 2026, reflecting the company’s strategic progress in advancing regenerative cardiac therapies.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed Inc. operates in the biotechnology industry, focusing on developing regenerative therapies for heart conditions. The company’s primary product is a cardiac remuscularization therapy using allogeneic iPS cell-derived cardiomyocyte spheroids, targeting severe heart failure caused by ischemic heart disease and dilated cardiomyopathy.
Average Trading Volume: 833,072
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen74.11B
See more insights into 219A stock on TipRanks’ Stock Analysis page.